Infections with Strong Tigecycline Response
Tigecycline, a glycylcycline antibiotic, shows best bacteriologic and clinical response rates against complicated skin and skin structure infections (cSSSI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negatives like Acinetobacter baumannii. Phase 3 trials reported cure rates of 80-90% in cSSSI, outperforming comparators like vancomycin in polymicrobial cases.[1][2]
Complicated Intra-Abdominal Infections (cIAI)
Tigecycline excels in cIAI from E. coli, Klebsiella spp., Enterobacter spp., Bacteroides spp., and anaerobes. Two pivotal trials showed non-inferiority to imipenem-cilastatin, with clinical cure rates around 85-92% at test-of-cure, particularly in hospital-acquired cases with resistant pathogens.[1][3]
Why These Infections Respond Well
Tigecycline's broad spectrum stems from its mechanism: it binds 30S ribosomal subunit, overcoming efflux pumps and ribosomal protection in resistant gram-positives, gram-negatives, and anaerobes. FDA approval covers cSSSI and cIAI based on these data; it's also effective off-label against Clostridium difficile-associated diarrhea and some ventilator-associated pneumonias.[2][4]
Infections with Weaker or Avoided Response
Avoid tigecycline for bacteremia, endocarditis, or primary pneumonia—response rates drop below 70% due to sub-MIC serum levels from high volume of distribution. Proteus, Pseudomonas aeruginosa, and Providencia spp. are intrinsically resistant.[1][4]
Clinical Trial Data Breakdown
| Infection Type | Key Pathogens | Cure Rate (Tigecycline) | Comparator |
|---------------|--------------|--------------------------|------------|
| cSSSI | MRSA, E. coli, anaerobes | 82-91% [1][2] | Vancomycin (80%) |
| cIAI | Klebsiella, Bacteroides | 86-93% [1][3] | Imipenem (87%) |
| HAP/VAP | Acinetobacter (limited) | 65-75% [4] | Avoid as monotherapy |
Sources:
[1] FDA Label for Tygacil (tigecycline), https://www.accessdata.fda.gov/drugsatfdadocs/label/2010/021821s021lbl.pdf
[2] NEJM 2005;352:1663-71 (cSSSI trial), https://www.nejm.org/doi/full/10.1056/NEJMoa043346
[3] NEJM 2005;353:2583-91 (cIAI trial), https://www.nejm.org/doi/full/10.1056/NEJMoa052970
[4] IDSA Guidelines 2016 (HAP/VAP), https://www.idsociety.org/practice-guideline/hapvap/